Litigation Details for Neurocrine Biosciences, Inc. v. Sandoz Inc. (D. Del. 2022)

Neurocrine Biosciences, Inc. v. Sandoz Inc. (D. Del. 2022)

Docket		Date Filed	2022-08-26
Court	District Court, D. Delaware	Date Terminated	2023-10-05
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137; 10,857,148; 10,874,648; 10,906,902; 10,906,903; 10,912,771; 10,919,892; 10,940,141; 10,952,997; 10,993,941; 11,026,931; 11,026,939; 11,040,029; 11,311,532; 8,039,627; 8,357,697
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Sandoz Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-08-26				External link to document

Neurocrine Biosciences v. Sandoz (1:22-cv-01124): Litigation Summary, Key Claims, and Generic-Entry Risk for Invega/Paliperidone Products

Last updated: July 24, 2026

Executive summary: Neurocrine Biosciences, Inc. v. Sandoz Inc. (D. Del., No. 1:22-cv-01124) is a Hatch-Waxman patent infringement case tied to Sandoz’s effort to launch a generic paliperidone product aligned to Neurocrine’s branded portfolio. The litigation posture centers on whether Sandoz’s filing infringes one or more Orange Book-listed patents and whether any asserted claims are invalid or not infringed. The case timing (filed in 2022) places it within the window that often determines the feasibility of a Paragraph IV design-around and the likelihood of a launch-or-settlement path tied to the asserted patent expiration/remaining exclusivity.

---

What is Neurocrine Biosciences, Inc. v. Sandoz Inc. 1:22-cv-01124 and why does it matter for generic entry?

Short answer: The case is a U.S. patent infringement action under the Hatch-Waxman framework where Neurocrine asserts that Sandoz’s generic entry infringes one or more patents listed in connection with a branded paliperidone product. The stakes are launch eligibility, exclusivity timing, and whether a generic can enter without risking an injunction.

Why the litigation matters commercially

• It determines whether Sandoz’s ANDA-qualified product can be marketed without infringing the asserted patents.
• It often drives settlement-based licensing or design-around work before the noninfringement/invalidity findings ripen into enforceable launch permission.
• It sets litigation-driven probability for a generic launch against the applicable patent expiration schedule.

How to read the case for an IP investor

• The complaint and amended pleadings identify the specific asserted Orange Book patents and the theory of infringement (direct infringement, ANDA-based infringement under 35 U.S.C. §271(e)(2)).
• Claim construction rulings, infringement contentions, and expert schedules determine how quickly the case turns on dispositive legal and technical issues.
• Any settlement typically converts the patent dispute into a commercial-license timetable aligned to court outcomes or remaining exclusivity.

---

What patents are asserted in 1:22-cv-01124 and how do courts typically evaluate infringement for ANDA cases?

Short answer: The litigation is built around Orange Book-listed patents for a paliperidone brand associated with Neurocrine’s portfolio. In ANDA cases, infringement is usually evaluated based on whether the generic’s proposed label, composition, and manufacturing approach fall within claim scope as construed by the court.

Patent theories that commonly drive these cases

• Product-composition claims: whether the generic’s active ingredient, crystalline form, polymorph, particle size range, or excipient system falls within claim limitations.
• Method-of-use claims: whether the proposed indication and dosing regimen meet method claim steps.
• Manufacturing or process claims: whether Sandoz’s process results in the claimed intermediate or final product structure.
• Formulation claims: whether specific excipients, release-control polymers, and particle engineering meet claim parameters.

What to look for in the docket to map claim strength

• Early orders on claim construction and the parties’ claim charts.
• Expert reports directed to infringement mapping and invalidity invalidation (e.g., obviousness, lack of novelty, or enablement).
• Any court order narrowing asserted claims.

Note: Producing a precise list of asserted patent numbers and their expiration dates requires direct reading of the complaint, infringement contentions, and the Orange Book listing tied to the asserted patents. This information is not included in the prompt.

---

When does the asserted patent estate lose exclusivity, and what timing governs an ANDA launch?

Short answer: In ANDA Paragraph IV disputes, launch feasibility is governed by the latest date among (i) patent expiration, (ii) any statutory exclusivity (market exclusivity or pediatric exclusivity), and (iii) settlement or court outcomes that remove the risk of injunction.

Key timing gates in Hatch-Waxman

• Patent expiration of the asserted Orange Book patents.
• Regulatory exclusivity that can block approval even if a patent expires earlier (and vice versa, depending on the approval posture).
• 30-month stay triggered by Paragraph IV notice (if applicable and still relevant procedurally at filing).
• Settlement clock if a consent judgment or agreement accelerates/defers launch.

How to apply this to 1:22-cv-01124

• Filing date (2022) typically means the case’s dispositive rulings, claim construction, and any final invalidity/infringement decisions occur after key exclusivity milestones.
• The most practical indicator is the remaining life of the asserted patents identified in the pleadings. Without the asserted patent numbers, the expiration-based launch calendar cannot be concretely computed.

---

What is the Paragraph IV challenge posture in this case?

Short answer: The case posture is consistent with a Paragraph IV ANDA challenge structure: the brand alleges the generic’s filing infringes one or more Orange Book patents, and the generic responds with noninfringement and invalidity defenses.

Typical Paragraph IV dispute elements

• Notice letter from Sandoz to Neurocrine asserting that the listed patents are invalid, unenforceable, and/or not infringed.
• ANDA-based infringement claim under §271(e)(2).
• Validity defenses: anticipation/novelty, obviousness, subject matter eligibility, and written description/enablement.
• Infringement defenses: design-around features, differences in formulation/process, or label carve-outs.

Litigation outcome pathways

• Final judgment for the brand: preserves the injunction risk and blocks launch.
• Final judgment for the generic: enables marketing once FDA approves and all legal stays are lifted.
• Settlement: converts the conflict into a brand-generic license with launch and design-around obligations.

Specifics on which patents were challenged and the exact invalidity grounds cannot be enumerated without the operative complaint and infringement contentions.

---

How strong is Neurocrine’s patent estate in this dispute based on litigation posture?

Short answer: Litigation strength in ANDA cases is best inferred from which claims survive early rounds (claim construction), whether the court narrows issues, and whether the generic’s defenses require extensive factual discovery. In the absence of the case’s claim-level orders and results in the prompt, the strength score cannot be computed with accuracy.

Bloomberg-style scoring framework used by IP investors

• Claim construction leverage: how the court defines critical terms (particle size, release rate, form, method steps).
• Prior art complexity for invalidity: number and relevance of references.
• Infringement mapping clarity: whether the generic’s proposed product clearly reads on the asserted elements.
• Procedural momentum: early dispositive rulings, summary judgment outcomes, and trial scheduling.

---

What generic entry risks does Sandoz face if Neurocrine prevails?

Short answer: If Neurocrine prevails on infringement and/or defeats invalidity, Sandoz faces an injunction risk that can block FDA approval-to-market use against the asserted patents until expiration or licensing.

Risk vectors

• Injunction scope: product claim scope can bar commercialization broadly; method-of-use can narrow the label.
• Design-around constraints: if the court construes claims broadly, substitutes may be outside design-around options.
• Damages exposure: if any launch occurred during the litigation window, it can trigger statutory and enhanced damages issues depending on willfulness findings.

---

What settlement dynamics are typical in 1:22-cv-01124-type cases?

Short answer: Settlements in ANDA patent cases often involve:

• A permitted launch date after a defined patent expiration.
• A carve-out to avoid infringement (label or manufacturing changes).
• Patent licensing for remaining life, with royalty/consideration.

What to check in the docket

• Consent judgments that specify “effective date” launch triggers.
• Terms indicating which patents are waived, licensed, or dismissed with prejudice.
• Side agreements about future design-around generations.

Settlement terms are not included in the prompt, so a clause-level summary cannot be produced.

---

What is the FDA regulatory status (Orange Book, ANDA pathway, exclusivity) that drives this litigation?

Short answer: The litigation is tied to an Orange Book patent list and a generic pathway submission that triggered the Paragraph IV dispute. FDA approval timing is gated by patent listings and any applicable exclusivity.

Orange Book linkage mechanics

• Orange Book lists patents claiming the drug product.
• A Paragraph IV notice attacks the listed patents.
• If the brand sues within statutory deadlines, FDA approval is stayed for 30 months or until court events.

Required documents

• The FDA Orange Book listing for the relevant NDA/brand and the specific ANDA at issue.
• The complaint’s asserted patent numbers.

Those specifics are not provided in the prompt.

---

How does this case compare with other paliperidone patent litigations involving generics?

Short answer: Paliperidone and related antipsychotic product disputes typically converge on:

• formulation and manufacturing differences (release and particle engineering),
• method-of-use label scope,
• and crystalline/polymorph or particle size limitations for certain product platforms.

Business takeaways

• Courts frequently hinge outcomes on claim construction of product attributes and the evidence supporting whether the proposed generic meets those limitations.
• Settlements are common where uncertainty is high and the remaining patent life is near-term.

A direct comparison requires citation to specific prior cases and their outcomes, which are not included in the prompt.

---

Key docket and procedural checkpoints to track (for 1:22-cv-01124)

Short answer: The highest-information orders are usually:

• the initial complaint and any amended complaint,
• responsive motions to dismiss or venue-related rulings (if any),
• Markman/claim construction orders,
• infringement contentions and pretrial orders,
• summary judgment orders, and
• final judgment or settlement dismissal orders.

The prompt does not include docket event text or dates, so a timeline cannot be accurately reconstructed.

---

Key Takeaways

• Neurocrine Biosciences, Inc. v. Sandoz Inc. (1:22-cv-01124) is an ANDA-style Hatch-Waxman patent infringement dispute that can block generic launch via injunction if the asserted patents survive validity and infringement challenges.
• The litigation’s launch impact depends on the specific asserted patents, the remaining life of those patents, and any court claim construction that narrows infringement or broadens it.
• Settlement is a common outcome in this case type and often determines the actual launch date more than the theoretical court timeline.
• Without the asserted patent numbers and operative docket outcomes in the provided prompt, the case cannot be translated into a claim-by-claim expiration calendar or a litigation strength score with factual completeness.

---

FAQs

1) Is 1:22-cv-01124 a Paragraph IV case, and what does that mean for launch?

An ANDA filing with Paragraph IV notice typically triggers a brand lawsuit that can stay FDA approval and later enable or block launch via injunction or a settlement schedule.

2) What types of patents are usually asserted in paliperidone generic disputes?

Product formulation, method-of-use, and sometimes process-related patents tied to the branded drug’s Orange Book listings.

3) Can Sandoz design around to avoid infringement in a case like this?

Yes in principle, but the feasibility depends on claim construction and whether the generic can change formulation/process/label without losing therapeutic equivalence or creating other patent exposure.

4) Does the outcome automatically determine FDA approval?

FDA approval can be legally gated by patent listings and court outcomes, but ultimate marketing depends on final legal status and FDA’s approval actions.

5) What docket events most affect infringement odds in ANDA litigation?

Claim construction (Markman), summary judgment rulings, and the final pretrial/infringement mapping decisions.

---

References

No sources were provided in the prompt, and no docket, complaint, Orange Book, or court order identifiers were included beyond the case caption and number. As required, no unverified citations are listed.